ASK REDCHAT ANYTHING ABOUT ZYMEWORKS INC.
Zymeworks Inc. (NASDAQ: ZYME)
Listen to this Section
$24.01
-0.1010
(
-0.42% )
230.2K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Zanidatamab (HER2)DetailsGastroesophageal adenocarcinomas, Cancer, CholangiocarcinomaBig Mover™Suspected Mover™Susp. Mover™ |
Phase 3 |
| Zanidatamab + Chemo/trastuzumabDetailsBreast cancer, Cancer, HER2-expressing cancers |
Phase 3 |
| Zanidatamab zovodotin (ZW49)DetailsHER2-expressing cancers, Cancer, Non-small cell lung carcinoma |
Phase 2 |
| Zanidatamab (HER2) + chemotherapy + tislelizumabDetailsCancer, Gastroesophageal adenocarcinomas, Cholangiocarcinoma |
Phase 2 |
| Zanidatamab (HER2) + docetaxelDetailsCancer, Breast cancer |
Phase 1/2 |
| ZW171DetailsCancer, Mesothelin-expressing solid tumors |
Phase 1 |
| ZW191DetailsCancer |
Phase 1 |
| Ziihera® (zanidatamab-hrii)DetailsCancer, Solid tumor/s, Biliary Tract Cancer |
Approved |
| ZW191DetailsCancer, Solid tumor/s |
Phase 1 |
Market Data
|
| Open |
$24.01 |
| Previous Close |
$24.11 |
| Volume |
230.2K |
| Market Cap |
$1.77B |
| Day Range |
$23.79 - $24.45 |
| 52 Week Range |
$11.51 - $29.75 |
| Shares Outstanding |
73.57M |
| Change % |
-0.42% |
| Net Change |
▼ -0.1010 |
| Insider Ownership |
-0.11% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | None |
| IPO Year | 2017 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
4,583,287.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-12-11 |
Sale |
-1550.00 |
Astle Christopher |
| 2023-12-08 |
Sale |
-37000.00 |
Campoy Carlos |
| 2023-12-08 |
Sale |
-37000.00 |
RENTON HOLLINGS |
| 2023-12-08 |
Sale |
-37000.00 |
Neu Kelvin |
| 2023-12-08 |
Sale |
-37000.00 |
Cox Troy |
| 2023-12-08 |
Sale |
-37000.00 |
Mahony Susan |
| 2023-12-08 |
Sale |
-37000.00 |
Miller Derek John Michael |
| 2023-12-08 |
Sale |
-74000.00 |
Davidson Nancy |
| 2023-12-08 |
Sale |
-37000.00 |
Hillan Kenneth J. |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| ars |
Annual reports |
1 |
Nov 10, 2025 |
| def |
Proxies and info statements |
23 |
Nov 10, 2025 |
| 10-q |
Quarterly Reports |
71 |
Nov 06, 2025 |
| 8-k |
8K-related |
14 |
Nov 06, 2025 |
| 8-k |
8K-related |
14 |
Sep 02, 2025 |
| 4 |
Insider transactions |
1 |
Aug 12, 2025 |
| 4 |
Insider transactions |
1 |
Aug 12, 2025 |
| 3 |
Insider transactions |
2 |
Aug 12, 2025 |
| 3 |
Insider transactions |
2 |
Aug 12, 2025 |
| 8-k |
8K-related |
15 |
Aug 11, 2025 |